Credit Suisse Ag Karuna Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$161.01 - $317.85 $1.36 Million - $2.69 Million	8,460 Added 27.44%	39,291 $12.4 Million
Q3 2023 Nov 13, 2023	SELL	$164.66 - $218.08 $137,655 - $182,314	-836 Reduced 2.64%	30,831 $5.21 Million
Q2 2023 Aug 11, 2023	BUY	$176.32 - $240.22 $1.23 Million - $1.68 Million	6,997 Added 28.36%	31,667 $6.87 Million
Q1 2023 May 10, 2023	BUY	$161.33 - $204.36 $272,647 - $345,368	1,690 Added 7.35%	24,670 $4.48 Million
Q4 2022 Feb 13, 2023	SELL	$191.53 - $236.82 $38,497 - $47,600	-201 Reduced 0.87%	22,980 $4.52 Million
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $613,874 - $1.38 Million	4,959 Added 27.21%	23,181 $5.21 Million
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $109,850 - $167,552	-1,169 Reduced 6.03%	18,222 $2.31 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $316,677 - $423,848	3,202 Added 19.78%	19,391 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $117,942 - $169,920	1,066 Added 7.05%	16,189 $2.12 Million
Q3 2021 Nov 12, 2021	BUY	$101.2 - $125.87 $350,860 - $436,391	3,467 Added 29.74%	15,123 $1.85 Million
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $469,878 - $594,509	-4,373 Reduced 27.28%	11,656 $1.33 Million
Q1 2021 May 14, 2021	SELL	$95.46 - $133.08 $621,158 - $865,951	-6,507 Reduced 28.87%	16,029 $1.93 Million
Q4 2020 Feb 12, 2021	SELL	$75.23 - $109.23 $301,672 - $438,012	-4,010 Reduced 15.11%	22,536 $2.29 Million
Q3 2020 Nov 13, 2020	SELL	$71.31 - $109.74 $361,470 - $556,272	-5,069 Reduced 16.03%	26,546 $2.05 Million
Q2 2020 Aug 12, 2020	BUY	$62.14 - $117.21 $1.96 Million - $3.71 Million	31,615 New	31,615 $3.52 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account